BerandaATHA • NASDAQ
add
Athira Pharma Inc
$0,64
Setelah Jam Perdagangan Normal:(0,47%)-0,0030
$0,64
Tutup: 22 Nov, 19.49.03 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$0,66
Rentang hari
$0,63 - $0,66
Rentang tahun
$0,41 - $4,30
Kapitalisasi pasar
24,64Â jt USD
Volume Rata-Rata
9,62Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
MSN
20 jam yang lalu
Wall Street Reli: Dow, S&P 500 dan Nasdaq Menguat, Ditopang Data Aktivitas
Bisnis
3,22%
0,35%
0,97%
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 25,49Â jt | -27,25% |
Laba bersih | -28,74Â jt | 12,83% |
Margin laba bersih | — | — |
Penghasilan per saham | — | — |
EBITDA | -25,25Â jt | 27,44% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 68,86Â jt | -60,19% |
Total aset | 86,25Â jt | -53,30% |
Total liabilitas | 28,66Â jt | -4,25% |
Total ekuitas | 57,58 jt | — |
Saham yang beredar | 38,67 jt | — |
Harga terhadap nilai buku | 0,44 | — |
Tingkat pengembalian aset | -64,54% | — |
Tingkat pengembalian modal | -88,74% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -28,74Â jt | 12,83% |
Kas dari operasi | -23,02Â jt | 4,01% |
Kas dari investasi | 18,04Â jt | -12,81% |
Kas dari pembiayaan | 12,00 rb | — |
Perubahan kas bersih | -4,97Â jt | -50,94% |
Arus kas bebas | -10,13Â jt | 13,86% |
Tentang
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Didirikan
2011
Kantor pusat
Situs
Karyawan
66
